Palmar plantar erythrodysesthesia causes

Jump to navigation Jump to search

Palmar plantar erythrodysesthesia Microchapters

Home

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Palmar plantar erythrodysesthesia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Palmar plantar erythrodysesthesia causes On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia causes

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Palmar plantar erythrodysesthesia causes

CDC on Palmar plantar erythrodysesthesia causes

Palmar plantar erythrodysesthesia causes in the news

Blogs on Palmar plantar erythrodysesthesia causes

Directions to Hospitals Treating Palmar plantar erythrodysesthesia

Risk calculators and risk factors for Palmar plantar erythrodysesthesia causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D.

Overview

Several different Chemotherapeutic agents have been associated with acral erythema[1]

Causes

Chemotherapy drugs that can cause this syndrome include:

Most frequently associated:


Less frequently associated:

  • Targeted therapy drugs can also cause PPE; however, the clinical and histologic patterns differ from the classic PPE caused by conventional cytotoxic chemotherapeutic agents. These include:
    • Axitinib (Inlyta) [67]
    • Cabozantinib (Cabometyx, Cometriq) [68]
    • Regorafenib (Stivarga)[69]
    • Pazopanibv(Votrient)[73]

References

  1. ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
  2. ↑ Baer MR, King LE, Wolff SN (1985). "Palmar-plantar erythrodysesthesia and cytarabine". Ann Intern Med. 102 (4): 556. doi:10.7326/0003-4819-102-4-556_1. PMID 3977204.
  3. ↑ Crawford JH, Eikelboom JW, McQuillan A (2002). "Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia". Eur J Haematol. 69 (5–6): 315–7. PMID 12460237.
  4. ↑ Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J; et al. (1995). "Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent". Arch Dermatol. 131 (2): 202–6. PMID 7857119.
  5. ↑ Katoh M, Kadota M, Nishimura Y (2004). "A case of docetaxel-induced erythrodysesthesia". J Dermatol. 31 (5): 403–6. PMID 15187308.
  6. ↑ Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK (1999). "Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs". Hum Exp Toxicol. 18 (1): 17–26. doi:10.1177/096032719901800103. PMID 10025364.
  7. ↑ Charrois GJ, Allen TM (2003). "Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity". J Pharmacol Exp Ther. 306 (3): 1058–67. doi:10.1124/jpet.103.053413. PMID 12808004.
  8. ↑ D'Agostino G, Ferrandina G, Ludovisi M, Testa A, Lorusso D, Gbaguidi N; et al. (2003). "Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer". Br J Cancer. 89 (7): 1180–4. doi:10.1038/sj.bjc.6601284. PMC 2394291. PMID 14520442.
  9. ↑ Vogelzang NJ, Ratain MJ (1985). "Cancer chemotherapy and skin changes". Ann Intern Med. 103 (2): 303–4. doi:10.7326/0003-4819-103-2-303_3. PMID 3160276.
  10. ↑ Coukell AJ, Spencer CM (1997). "Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma". Drugs. 53 (3): 520–38. doi:10.2165/00003495-199753030-00011. PMID 9074848.
  11. ↑ Goram AL, Richmond PL (2001). "Pegylated liposomal doxorubicin: tolerability and toxicity". Pharmacotherapy. 21 (6): 751–63. PMID 11401188.
  12. ↑ Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y; et al. (2004). "Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer". Ann Oncol. 15 (3): 517–25. doi:10.1093/annonc/mdh092. PMID 14998859.
  13. ↑ Molpus KL, Anderson LB, Craig CL, Puleo JG (2004). "The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma". Gynecol Oncol. 93 (2): 513–6. doi:10.1016/j.ygyno.2004.02.019. PMID 15099971.
  14. ↑ Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE (1998). "Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model". Clin Cancer Res. 4 (6): 1567–71. PMID 9626479.
  15. ↑ Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989). "A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study". J Clin Oncol. 7 (4): 425–32. doi:10.1200/JCO.1989.7.4.425. PMID 2926468.
  16. ↑ Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R (1990). "Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion". Invest New Drugs. 8 (1): 57–63. PMID 2345070.
  17. ↑ Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P; et al. (1991). "A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma". J Clin Oncol. 9 (4): 625–30. doi:10.1200/JCO.1991.9.4.625. PMID 2066758.
  18. ↑ Banfield GK, Crate ID, Griffiths CL (1995). "Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy". J R Soc Med. 88 (6): 356P–357P. PMC 1295248. PMID 7629773.
  19. ↑ Bellmunt J, Navarro M, Hidalgo R, Solé LA (1988). "Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil". Tumori. 74 (3): 329–31. PMID 3400123.
  20. ↑ Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C; et al. (1997). "Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion". Eur J Cancer. 33 (6): 967–9. PMID 9291822.
  21. ↑ Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R; et al. (1993). "Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment". Anticancer Res. 13 (5C): 1781–3. PMID 8267382.
  22. ↑ Curran CF, Luce JK (1989). "Fluorouracil and palmar-plantar erythrodysesthesia". Ann Intern Med. 111 (10): 858. doi:10.7326/0003-4819-111-10-858_1. PMID 2817635.
  23. ↑ Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M; et al. (2001). "Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study". J Clin Oncol. 19 (8): 2282–92. doi:10.1200/JCO.2001.19.8.2282. PMID 11304782.
  24. ↑ Iurlo A, Fornier M, Caldiera S, Bertoni F, Foa P (1997). "Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?". Acta Oncol. 36 (6): 653–4. PMID 9408159.
  25. ↑ Leo S, Tatulli C, Taveri R, Campanella GA, Carrieri G, Colucci G (1994). "Dermatological toxicity from chemotherapy containing 5-fluorouracil". J Chemother. 6 (6): 423–6. PMID 7699432.
  26. ↑ Meta-Analysis Group In Cancer. Lévy E, Piedbois P, Buyse M, Pignon JP, Rougier P; et al. (1998). "Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors". J Clin Oncol. 16 (11): 3537–41. doi:10.1200/JCO.1998.16.11.3537. PMID 9817272.
  27. ↑ Macdonald JS (1999). "Toxicity of 5-fluorouracil". Oncology (Williston Park). 13 (7 Suppl 3): 33–4. PMID 10442356.
  28. ↑ Mortimer JE, Anderson I (1990). "Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity". Cancer Chemother Pharmacol. 26 (6): 449–52. PMID 2225317.
  29. ↑ Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS; et al. (2002). "Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer". J Clin Oncol. 20 (6): 1491–8. doi:10.1200/JCO.2002.20.6.1491. PMID 11896096.
  30. ↑ Lassere Y, Hoff P (2004). "Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)". Eur J Oncol Nurs. 8 Suppl 1: S31–40. doi:10.1016/j.ejon.2004.06.007. PMID 15341880.
  31. ↑ Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D; et al. (2001). "Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer". Ann Oncol. 12 (9): 1247–54. doi:10.1023/a:1012281104865. PMID 11697835.
  32. ↑ Abushullaih S, Saad ED, Munsell M, Hoff PM (2002). "Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience". Cancer Invest. 20 (1): 3–10. PMID 11853000.
  33. ↑ Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C; et al. (1999). "Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer". J Clin Oncol. 17 (2): 485–93. doi:10.1200/JCO.1999.17.2.485. PMID 10080589.
  34. ↑ Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M; et al. (2002). "First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin". Ann Oncol. 13 (4): 566–75. doi:10.1093/annonc/mdf089. PMID 12056707.
  35. ↑ Sternberg CN, Reichardt P, Holland M (2004). "Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours". Eur J Oncol Nurs. 8 Suppl 1: S4–15. doi:10.1016/j.ejon.2004.06.005. PMID 15341878.
  36. ↑ Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M; et al. (2001). "Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study". J Clin Oncol. 19 (21): 4097–106. doi:10.1200/JCO.2001.19.21.4097. PMID 11689577.
  37. ↑ Vakalis D, Ioannides D, Lazaridou E, Mattheou-Vakali G, Teknetzis A (1998). "Acral erythema induced by chemotherapy with cisplatin". Br J Dermatol. 139 (4): 750–1. PMID 9892931.
  38. ↑ Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J (1991). "The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation". Br J Haematol. 77 (4): 529–34. PMID 2025579.
  39. ↑ Hui YF, Cortes JE (2000). "Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin". Pharmacotherapy. 20 (10): 1221–3. PMID 11034047.
  40. ↑ Marigny K, Aubin F, Burgot G, Le Gall E, Gandemer V (2005). "Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?". Cancer Chemother Pharmacol. 55 (3): 244–50. doi:10.1007/s00280-004-0858-2. PMID 15526203.
  41. ↑ Murphy CP, Harden EA, Herzig RH (1993). eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8490845 "Dose-related cutaneous toxicities with etoposide" Check |url= value (help). Cancer. 71 (10): 3153–5. doi:10.1002/1097-0142(19930515)71:10<3153::aid-cncr2820711042>3.0.co;2-#. PMID 8490845.
  42. ↑ Portal I, Cardenal F, Garcia-del-Muro X (1994). "Etoposide-related acral erythema". Cancer Chemother Pharmacol. 34 (2): 181. PMID 8194170.
  43. ↑ Schey SA, Cooper J, Summerhayes M (1992). "The "handfoot syndrome" occurring with chronic administration of etoposide". Eur J Haematol. 48 (2): 118–9. PMID 1547875.
  44. ↑ Neuss MN, Akwari OE, Stevenson DF, Goodwin BJ (1987). "Painful palmar and plantar erythema associated with hepatic artery infusion of 5-fluoro-2'deoxyuridine". J Natl Med Assoc. 79 (6): 669–71. PMC 2625536. PMID 2956430.
  45. ↑ Vassallo C, Passamonti F, Merante S, Ardigò M, Nolli G, Mangiacavalli S; et al. (2001). "Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia". Clin Exp Dermatol. 26 (2): 141–8. PMID 11298103.
  46. ↑ Cox GJ, Robertson DB (1986). "Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy". Arch Dermatol. 122 (12): 1413–4. PMID 2947543.
  47. ↑ Azurdia RM, Clark RE, Friedmann PS (1999). "Chemotherapy-induced acral erythema (CIAE) with bullous reaction". Clin Exp Dermatol. 24 (2): 64–6. PMID 10233654.
  48. ↑ Hansen RM, Quebbeman EJ, Ritch PS, Frick J, Anderson T (1987). "Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity". Am J Clin Oncol. 10 (3): 216–8. PMID 3496002.
  49. ↑ Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ (1996). "High-dose methotrexate-induced bullous variant of acral erythema". Arch Dermatol. 132 (5): 590–1. PMID 8624164.
  50. ↑ Ikeda H, Kawano H, Kitaura T, Kimura A, Kihira K (1999). "Acral erythema associated with high-dose methotrexate infusion". Ann Pharmacother. 33 (5): 646. PMID 10369634.
  51. ↑ Morrell DS, Challgren E, Eapen M, Esterly NB (2002). "Bullous acral erythema secondary to high-dose methotrexate". J Pediatr Hematol Oncol. 24 (3): 240. PMID 11990316.
  52. ↑ Postovsky S, Ben Arush MW (2005). "Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma". Pediatr Hematol Oncol. 22 (2): 167–73. doi:10.1080/08880010590907320. PMID 15805003.
  53. ↑ Zuehlke RL (1974). "Erythematous eruption of the palms and soles associated with mitotane therapy". Dermatologica. 148 (2): 90–2. PMID 4276191.
  54. ↑ Kupfer I, Balguerie X, Courville P, Chinet P, Joly P (2003). "Scleroderma-like cutaneous lesions induced by paclitaxel: a case study". J Am Acad Dermatol. 48 (2): 279–81. doi:10.1067/mjd.2003.30. PMID 12582404.
  55. ↑ Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N; et al. (2002). "Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors". Oncology. 62 (3): 216–22. doi:10.1159/000059568. PMID 12065868.
  56. ↑ Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S; et al. (2002). "Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel". Clin Cancer Res. 8 (3): 670–8. PMID 11895894.
  57. ↑ Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P; et al. (2001). "A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients". Ann Oncol. 12 (5): 605–14. doi:10.1023/a:1011181010669. PMID 11432617.
  58. ↑ Bastida J, Díaz-Cascajo C, Borghi S (1997). "Chemotherapy-induced acral erythema due to Tegafur". Acta Derm Venereol. 77 (1): 72–3. doi:10.2340/00015555777273. PMID 9059686.
  59. ↑ Jucglà A, Sais G, Navarro M, Peyri J (1995). "Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur". Arch Dermatol. 131 (3): 364–5. PMID 7887678.
  60. ↑ Rios-Buceta L, Buezo GF, Peñas PF, Dauden E, Fernandez-Herrera J, Garcia-Diez A (1997). "Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur". Acta Derm Venereol. 77 (1): 80–1. doi:10.2340/00015555778081. PMID 9059693.
  61. ↑ Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN (1998). "Hand-foot syndrome following prolonged infusion of high doses of vinorelbine". Cancer. 82 (5): 965–9. doi:10.1002/(sici)1097-0142(19980301)82:5<965::aid-cncr23>3.0.co;2-y. PMID 9486588.
  62. ↑ Laack E, Mende T, Knuffmann C, Hossfeld DK (2001). "Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine". Ann Oncol. 12 (12): 1761–3. doi:10.1023/a:1013575816870. PMID 11843256.
  63. ↑ Lorusso V, Crucitta E, Silvestris N, Guida M, Misino A, Latorre A; et al. (2003). "A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer". Clin Breast Cancer. 4 (2): 138–41. PMID 12864942.
  64. ↑ Rosner F (1998). "Hand-foot syndrome following prolonged infusion of high doses of vinorelbine". Cancer. 83 (5): 1054–5. doi:10.1002/(sici)1097-0142(19980901)83:5<1054::aid-cncr40>3.0.co;2-3. PMID 9731914.
  65. ↑ Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D; et al. (2013). "Analysis of dermatologic events in vemurafenib-treated patients with melanoma". Oncologist. 18 (3): 314–22. doi:10.1634/theoncologist.2012-0333. PMC 3607529. PMID 23457002.
  66. ↑ Powell BL, Lyerly ES, Motsinger CP, Cruz JM, Chorley HM, Hurd DD; et al. (1995). "Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia". Leukemia. 9 (5): 770–3. PMID 7769838.
  67. ↑ Fischer A, Wu S, Ho AL, Lacouture ME (2013). "The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis". Invest New Drugs. 31 (3): 787–97. doi:10.1007/s10637-013-9927-x. PMID 23345001.
  68. ↑ Belum VR, Serna-Tamayo C, Wu S, Lacouture ME (2016). "Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis". Clin Exp Dermatol. 41 (1): 8–15. doi:10.1111/ced.12694. PMC 5066302. PMID 26009777.
  69. ↑ Kobayashi K, Kawakami K, Yokokawa T, Aoyama T, Suzuki K, Wakatsuki T; et al. (2019). "Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer". Oncology. 96 (4): 200–206. doi:10.1159/000495989. PMID 30763946.
  70. ↑ 70.0 70.1 Velandia-Carrillo C, Wandurraga-Sánchez E, Gómez-Abreo D (2014). "Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report". BMC Endocr Disord. 14: 26. doi:10.1186/1472-6823-14-26. PMC 3994654. PMID 24641872.
  71. ↑ 71.0 71.1 Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH; et al. (2009). "Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib". Br J Dermatol. 161 (5): 1045–51. doi:10.1111/j.1365-2133.2009.09290.x. PMID 19558553.
  72. ↑ 72.0 72.1 Lacouture ME, Reilly LM, Gerami P, Guitart J (2008). "Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib". Ann Oncol. 19 (11): 1955–61. doi:10.1093/annonc/mdn389. PMID 18550575.
  73. ↑ Sundriyal D, Kumar N (2015). "Pazopanib induced hand-foot syndrome". Oxf Med Case Reports. 2015 (2): 206–7. doi:10.1093/omcr/omv013. PMC 4370017. PMID 25988081.
Retrieved from "https://www.wikidoc.org/index.php?title=Palmar_plantar_erythrodysesthesia_causes&oldid=1574406"